This better survival is associated, for the French XP patients originating from North Africa and bearing the same founder mutation in the XPC gene, with a very high risk to develop aggressive and lethal internal cancers, particularly hematological malignancies, and brain, gynecological, and thyroid tumors. This evidence concerns the gene XPC and hematologic disorder.